DK1268775T3 - Höjt knoglemassegen af 11Q13.3 - Google Patents

Höjt knoglemassegen af 11Q13.3

Info

Publication number
DK1268775T3
DK1268775T3 DK00941578T DK00941578T DK1268775T3 DK 1268775 T3 DK1268775 T3 DK 1268775T3 DK 00941578 T DK00941578 T DK 00941578T DK 00941578 T DK00941578 T DK 00941578T DK 1268775 T3 DK1268775 T3 DK 1268775T3
Authority
DK
Denmark
Prior art keywords
methods
present
bone mass
gene
diagnosing
Prior art date
Application number
DK00941578T
Other languages
English (en)
Inventor
Randall D Little
John P Carulli
Robert R Recker
Mark L Johnson
Original Assignee
Oscient Pharmaceuticals Corp
Univ Creighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/544,398 external-priority patent/US6770461B1/en
Application filed by Oscient Pharmaceuticals Corp, Univ Creighton filed Critical Oscient Pharmaceuticals Corp
Priority claimed from PCT/US2000/016951 external-priority patent/WO2001077327A1/en
Application granted granted Critical
Publication of DK1268775T3 publication Critical patent/DK1268775T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
DK00941578T 2000-04-05 2000-06-21 Höjt knoglemassegen af 11Q13.3 DK1268775T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/543,771 US6780609B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 1.1q13.3
US09/544,398 US6770461B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 11q13.3
PCT/US2000/016951 WO2001077327A1 (en) 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3

Publications (1)

Publication Number Publication Date
DK1268775T3 true DK1268775T3 (da) 2009-03-16

Family

ID=32851157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00941578T DK1268775T3 (da) 2000-04-05 2000-06-21 Höjt knoglemassegen af 11Q13.3

Country Status (7)

Country Link
US (2) US6780609B1 (da)
EP (1) EP1964921A3 (da)
AT (1) ATE414772T1 (da)
DE (1) DE60040870D1 (da)
DK (1) DK1268775T3 (da)
ES (1) ES2316370T3 (da)
ZA (1) ZA200207883B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770461B1 (en) * 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
EP2363480A3 (en) * 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
CN103038258B (zh) 2010-05-06 2017-02-15 诺华股份有限公司 用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4973666A (en) 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
US6545137B1 (en) 1997-04-15 2003-04-08 John A. Todd Receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
FR2768747B1 (fr) 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
DE60129433T2 (de) * 2000-05-26 2008-04-17 Oscient Pharmaceuticals Corp., Waltham Regulation des lipidniveaus über die gene zmax1 oder hbm
EP1483288A4 (en) * 2001-05-11 2005-09-21 Genome Therapeutics Corp HBM VARIANTS MODULATING BONE MASS AND LIPID LEVELS
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
KR102371587B1 (ko) 2015-05-22 2022-03-07 현대자동차주식회사 횡단보도 인식 결과를 이용한 안내 정보 제공 장치 및 방법

Also Published As

Publication number Publication date
EP1964921A2 (en) 2008-09-03
ZA200207883B (en) 2004-01-27
US20050142617A1 (en) 2005-06-30
DE60040870D1 (de) 2009-01-02
ES2316370T3 (es) 2009-04-16
EP1964921A3 (en) 2008-12-03
US6780609B1 (en) 2004-08-24
ATE414772T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
MXPA03010077A (es) Abonadora de siembra a voleo con deflector movible.
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
ATE371727T1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
ATE553201T1 (de) Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
DK1124846T3 (da) Nukleotid- og proteinsekvenser af Nogo-gener og derpå baserede fremgangsmåder
MXPA02009791A (es) El gen de alta masa osea de 11q13.3.
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DK1268775T3 (da) Höjt knoglemassegen af 11Q13.3
ATE329026T1 (de) In knorpelgeweben stark exprimiertes gen
DK1285002T3 (da) Regulering af lipidniveauer ved hjælp af ZMAX1- eller HBM-genet
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
FI940036A0 (fi) Nukleotidisekvenssejä ja sykloheksimidiresistenssejä proteiineja
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
JP2005535289A5 (da)
ATE483019T1 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
Gronenborn et al. Overproduction of the cyclic AMP receptor protein of Escherichia coli and expression of the engineered C-terminal DNA-binding domain
DK0778347T3 (da) Protein med formodede helicase- og ATPase-egenskaber, som binder ATP og nukleinsyre
BR9811501A (pt) Sequência de nucleotìdeos do gene nucleocapsìdeo de vìrus oropouche
DE69813837D1 (de) Gen des familiären mittelmeerfiebers
MX9703970A (es) Quimiocinas expresadas, su produccion y usos.